IndustryCompany release

Karyopharm and KPT Texas line up prepackaged Chapter 11 with full creditor backing

🇺🇸 Karyopharm Therapeutics Inc. (KPTI) · Tue 03 Nov 2026

Karyopharm Therapeutics and affiliate KPT Texas LLC have begun soliciting votes on a prepackaged Chapter 11 plan, with every voting creditor class signed up to a restructuring support agreement.

Karyopharm Therapeutics Inc. and its affiliate KPT Texas LLC have circulated a disclosure statement to solicit votes on a prepackaged Chapter 11 plan. The plan is to be filed in the U.S. Bankruptcy Court for the Southern District of Texas.

Holders of 100% of the term loan, the 2028 notes, the 2029 notes, the royalty (RIFA) claims and the existing preferred interests have signed a restructuring support agreement. The voting deadline is 30 November 2026.

The companies say they intend to keep operating normally during the process. They plan to pay trade creditors, customers and employees in full.

The plan still requires confirmation by the court. The summary provided does not detail the plan's financial terms or the timetable for confirmation.

What it means for your team

  • Companies with Karyopharm as a supplier or partner should note that trade creditors and customers are slated to be paid in full, but this depends on the court confirming the plan.
  • Regulatory, pharmacovigilance and quality teams with dependencies on Karyopharm should watch for confirmation of continued operations and for any later court filings.
  • Market-access and commercial contacts should follow the 30 November 2026 voting deadline and the subsequent court process, as the available details are limited.

Company's press release (SEC filing): Karyopharm Therapeutics Inc. ↗

Article written by VigiEye from the official source (Karyopharm Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →